Biotech startups in Hangzhou, China
Updated 16 Nov 2026
Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Company | City | Last round | Amount | Date |
|---|---|---|---|---|
| AusperBio | Hangzhou | Series C | $120.0M | 2026-08-27 |
| METiS Pharmaceuticals | Hangzhou | Series D | $55.7M | 2025-08-04 |
| LYNK Pharmaceuticals | Hangzhou | Series C | $16.7M | 2023-09-21 |
| DXY | Hangzhou | Series E | $500.0M | 2020-12-29 |
| Prime Lifescience | Hangzhou | Series A | $14.7M | 2026-06-30 |
| DIAGENS | Hangzhou | Series C | $14.1M | 2023-12-29 |
| Qihan Biotech | Hangzhou | Series B | $16.0M | 2023-09-15 |
| Dishi Medical | Hangzhou | Series A | $13.7M | 2026-01-19 |
8 rows of the CSV in 5 of its 18 columns.
- The 129 biotech startups in Hangzhou, China have raised $3.7B in total.
- 28 of them closed their most recent round in the last 12 months, $425.3M combined.
- The largest of those rounds is AusperBio's $120.0M Series C, dated August 2026.
- The most recent is Qiantang Longyue's $14.9M Series B on 17 September 2026.
- Legend Capital is an investor in 3 of them, more than any other fund.
- Health care is the most common other sector, with 108 companies (84%).
- 42% were founded in 2020 or later; the median founding year is 2018.
- The most common team size is 11 to 50 employees (46% of companies with a recorded size).
- 1 is a unicorn, valued at $1 billion or more.
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Newest rounds
10 of 129| Company | What they do | Sector | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|
| AusperBio | AusperBio develops oligonucleotide therapeutics and targeted delivery technologies for treating diseases. | Biotech | Series C | $120.0M | 2026-08-27 | $357.0M | Qiming Venture Partners, BioVenture, Hankang Capital +1 | 51 to 100 | 2019 |
| Prime Lifescience | Prime Lifescience develops a big data platform for life sciences research and analysis. | Biotech | Series A | $14.7M | 2026-06-30 | $44.5M | Qiming Venture Partners, Qiji Investment, Ennovation Ventures | 11 to 50 | 2021 |
| Dishi Medical | Dishi Medical manufactures ophthalmic medical devices and micro-assisted robots supported by biotechnology. | Biotech | Series A | $13.7M | 2026-01-19 | $13.7M | Hillhouse Investment, Fortune Venture Capital, Linear Capital +1 | 11 to 50 | 2021 |
| Levinthal | Levinthal uses artificial intelligence for protein design and co-evolution in food safety and medical care. | Artificial intelligence | Seed | $1K | 2025-12-09 | $1.6M | ZhenFund, Kaitai Capital, Pan-Lin Capital +1 | 1 to 10 | 2021 |
| Healsun Biopharm | Healsun Biopharm provides antibody and recombinant protein CRO and CDMO services. | Biotech | Series C | $27.8M | 2025-11-19 | $101.3M | Yinxinggu Capital, Haitong Capital, Dongfang Jiafu +2 | 251 to 500 | 2015 |
| METiS Pharmaceuticals | METiS Pharmaceuticals is an AI-driven drug formulation company. | Artificial intelligence | Series D | $55.7M | 2025-08-04 | $391.7M | Source Code Capital, Frees Fund, Luminous Ventures (former Lightspeed China Partners) | 51 to 100 | 2020 |
| DIAGENS | DIAGENS is a Hangzhou-based biotechnology firm that provides in-vitro diagnostic products and medical equipment. | Biotech | Series C | $14.1M | 2023-12-29 | Shenzhen Guozhong Venture Capital Management, Haiyuan Capital, China Venture Capital HRVC +2 | 51 to 100 | 2014 | |
| LYNK Pharmaceuticals | LYNK Pharmaceuticals is a biotech company that discovers and develops new medicines. | Biotech | Series C | $16.7M | 2023-09-21 | Legend Capital, Kaitai Capital, New Alliance Capital +2 | 11 to 50 | 2018 | |
| Qihan Biotech | Qihan Biotech develops gene-editing technology for organ transplantation. | Biotech | Series B | $16.0M | 2023-09-15 | $116.3M | Matrix Partners China, Northern Light Venture Capital, CMB International Capital Corporation +1 | 101 to 250 | 2017 |
| DXY Unicorn | DXY is an online healthcare community connecting doctors, consumers, and healthcare organizations. | Biotech | Series E | $500.0M | 2020-12-29 | $682.0M | Shunwei Capital, DCM Ventures, Legend Capital +1 | 101 to 250 | 2000 |
Table 1. Biotech startups in Hangzhou, China: the 10 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 129.
Largest rounds
Last 12 months| # | Company | What they do | Sector | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | AusperBio | AusperBio develops oligonucleotide therapeutics and targeted delivery technologies for treating diseases. | Biotech | Series C | $120.0M | 2026-08-27 | $357.0M | Qiming Venture Partners, BioVenture, Hankang Capital +1 | 51 to 100 | 2019 |
| 2 | Healsun Biopharm | Healsun Biopharm provides antibody and recombinant protein CRO and CDMO services. | Biotech | Series C | $27.8M | 2025-11-19 | $101.3M | Yinxinggu Capital, Haitong Capital, Dongfang Jiafu +2 | 251 to 500 | 2015 |
| 3 | Prime Lifescience | Prime Lifescience develops a big data platform for life sciences research and analysis. | Biotech | Series A | $14.7M | 2026-06-30 | $44.5M | Qiming Venture Partners, Qiji Investment, Ennovation Ventures | 11 to 50 | 2021 |
| 4 | Dishi Medical | Dishi Medical manufactures ophthalmic medical devices and micro-assisted robots supported by biotechnology. | Biotech | Series A | $13.7M | 2026-01-19 | $13.7M | Hillhouse Investment, Fortune Venture Capital, Linear Capital +1 | 11 to 50 | 2021 |
| 5 | Levinthal | Levinthal uses artificial intelligence for protein design and co-evolution in food safety and medical care. | Artificial intelligence | Seed | $1K | 2025-12-09 | $1.6M | ZhenFund, Kaitai Capital, Pan-Lin Capital +1 | 1 to 10 | 2021 |
Table 2. Biotech startups in Hangzhou, China: the 5 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most active investors
By companies backed| # | Investor | Type | Location | Companies | Share | Funded, 12 months | Latest |
|---|---|---|---|---|---|---|---|
| 1 | Legend Capital | Venture capital firm | Beijing, China | 3 | 2% | ||
| 2 | Puhua Capital | Venture capital firm | Hangzhou, China | 3 | 2% | ||
| 3 | Pan-Lin Capital | Venture capital firm | Shanghai, China | 3 | 2% | 1 | Levinthal |
| 4 | Qiming Venture Partners | Venture capital firm | Shanghai, China | 2 | 2% | 2 | AusperBio, Prime Lifescience |
| 5 | Source Code Capital | Venture capital firm | Chaoyang, China | 2 | 2% | ||
| 6 | Kaitai Capital | Venture capital firm | Hangzhou, China | 2 | 2% | 1 | Levinthal |
| 7 | Lilly Asia Ventures | Venture capital firm | Shanghai, China | 2 | 2% | ||
| 8 | Qiji Investment | Venture capital firm | Suzhou, China | 2 | 2% | 1 | Prime Lifescience |
| 9 | Haiyuan Capital | Venture capital firm | Shenzhen, China | 2 | 2% | ||
| 10 | Matrix Partners China | Venture capital firm | Beijing, China | 2 | 2% | ||
| 11 | Fortune Venture Capital | Venture capital firm | Shenzhen, China | 2 | 2% | 1 | Dishi Medical |
| 12 | Xinghua Dingli | Venture capital firm | 2 | 2% | |||
| 13 | Yinxinggu Capital | Venture capital firm | Hangzhou, China | 2 | 2% | 1 | Healsun Biopharm |
| 14 | Prox Ventures | Venture capital firm | Shanghai, China | 2 | 2% | ||
| 15 | ZhenFund | Entrepreneurship program | Beijing, China | 2 | 2% | 1 | Levinthal |
Table 3. Biotech startups in Hangzhou, China: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Sectors
| Sectors | Companies | Share | Total raised |
|---|---|---|---|
| Health care | 108 | 84% | $3.3B |
| Software | 7 | 5% | $1.1B |
| Artificial intelligence | 5 | 4% | $414.6M |
| Hardware | 4 | 3% | |
| Energy | 1 | 1% | $7.4M |
Table 4. Biotech startups in Hangzhou, China by sector. Source: FundingWatcher. Data as of 16 November 2026.
Funding stage
Table 5. Biotech startups in Hangzhou, China by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Rounds by month
| Rounds by month | Companies | Share | Raised |
|---|---|---|---|
| October 2026 | 1 | 4% | |
| September 2026 | 3 | 11% | $16.4M |
| August 2026 | 4 | 14% | $163.1M |
| July 2026 | 2 | 7% | $21.4M |
| June 2026 | 3 | 11% | $59.0M |
| April 2026 | 3 | 11% | $23.2M |
| March 2026 | 3 | 11% | $21.9M |
| February 2026 | 2 | 7% | $28.8M |
| January 2026 | 2 | 7% | $20.9M |
| December 2025 | 4 | 14% | $42.6M |
| November 2025 | 1 | 4% | $27.8M |
Table 6. Biotech startups in Hangzhou, China: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most recent round by year
| Most recent round by year | Companies | Share | Raised |
|---|---|---|---|
| 2026 | 23 | 18% | $354.9M |
| 2025 | 28 | 22% | $355.0M |
| 2024 | 14 | 11% | $73.8M |
| 2023 | 22 | 17% | $125.4M |
| 2022 | 11 | 9% | $36.6M |
| 2021 | 9 | 7% | $625.1M |
Table 7. Biotech startups in Hangzhou, China by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Founding year
| Founding year | Companies | Share |
|---|---|---|
| 2023 or later | 18 | 14% |
| 2020 to 2022 | 36 | 28% |
| 2015 to 2019 | 43 | 34% |
| 2010 to 2014 | 22 | 17% |
| Before 2010 | 9 | 7% |
Table 8. Biotech startups in Hangzhou, China by founding year. Source: FundingWatcher. Data as of 16 November 2026.
Team size
| Team size | Companies | Share |
|---|---|---|
| 1 to 10 | 8 | 9% |
| 11 to 50 | 43 | 46% |
| 51 to 100 | 24 | 26% |
| 101 to 250 | 13 | 14% |
| 251 to 500 | 2 | 2% |
| 501 to 1,000 | 2 | 2% |
| 1,001 to 5,000 | 1 | 1% |
Table 9. Biotech startups in Hangzhou, China by headcount. Source: FundingWatcher. Data as of 16 November 2026.
Method
- A company is on this list when Biotech is one of its sectors and its headquarters is in Hangzhou, China. On 16 November 2026 that is 129 companies.
- Stage, round, amount and date are those of the company's most recent funding round. Amounts are in US dollars as the source records them.
- The table prints the 10 newest rounds whose row is complete: a one-sentence description, a city, a named fund and an amount. The CSV carries all 129 rows: 59 have no round amount, 0 no city and 47 no website. The CSV carries domain, website, LinkedIn and the cached description sentence where present.
Sources, fields and exclusions of both files: Method.
Questions
- How many biotech startups in Hangzhou, China are on the list?
- 129, in the file dated 16 November 2026. 28 of them closed their most recent round in the last 12 months.
- What does the CSV contain?
- One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
- How much does the list cost?
- $29 one-time for all 129 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
- What arrives after payment?
- At once: the CSV download link, on the page after payment and by mail.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.